Blog

Razelle Kurzrock: Expanding HER2 horizons – Implications for NSCLC and beyond

Razelle Kurzrock/froedtert.com

Nov 2, 2024, 05:07

Razelle Kurzrock: Expanding HER2 horizons – Implications for NSCLC and beyond

Razelle Kurzrock, Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center, shared this post on X:

“HER2 is incredible target. Her2 IhC should be done on every cancer since Enhertu has tissue-agnostic approval.

My experience is that Enhertu works really well (including in pts with her2 1+ or 2+). But we dose reduce (prefer 2.7 mg/kg IV q3wks to start rather than 5.4 mg/kg).”

touchONCOLOGY, shared this post on X:

“HER2 targeting insights!

Join leading experts Dr Razelle Kurzrock, Dr Lyudmila Bazhenova and Dr Ignacio Wistuba as they explore HER2 targeting in Solid Tumours, focusing on NSCLC.

Click here to watch the video.”

Razelle Kurzrock: Expanding HER2 horizons - Implications for NSCLC and beyond

Razelle Kurzrock, is a world-renowned physician-scientist leader in precision medicine as well as in the development of novel therapeutics in the field of oncology. She is recognized for founding, developing and chairing one of the largest Phase 1 clinical trial departments globally while at the University of Texas MD Anderson Cancer Center; the central theme of the department was a personalized medicine strategy. She is also one of the pioneering trialists of the WINTHER precision medicine international trial focusing, for the first time, on transcriptomics in addition to genomics. This trial was the signature study of the Worldwide Innovative Network (WIN) consortium (Nature Medicine). She also developed and led some of the first tumor-agnostic cancer clinical trials.